Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 20%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics is a biotechnology company with a positive outlook due to their innovative approach to restoring protein expression using RNA medicine, as well as their strong pipeline with multiple potential disease-modifying therapies. The recent enrollment of 150 patients for their P3 trial and the potential for early FDA approval based on beyond-seizure effects of their first medicine, zorevunersen, indicate strong operational excellence and transformational potential. Based on our valuation analysis, we believe the stock is undervalued and have set a 12-month price target of $35 per share. However, the company still faces risks such as clinical readouts, regulatory uncertainty, and potential patent disputes.

Bears say

Stoke Therapeutics is facing several risks that may affect its success, including low likelihood of success in attaining regulatory approval for its drug candidates and dependence on third-party data. Additionally, the company will need to raise additional capital before it becomes profitable, which may result in share dilution for shareholders. The high volatility of the stock price and potential challenges in gaining market acceptance for its products may also impact the company's overall financial outlook.

STOK has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 20% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 10 analysts, STOK has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.